A

Arena Pharmaceuticals Inc
F:RN3N

Watchlist Manager
Arena Pharmaceuticals Inc
F:RN3N
Watchlist
Price: 90.5 EUR 0.56%
Market Cap: 5.6B EUR

Arena Pharmaceuticals Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Arena Pharmaceuticals Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Arena Pharmaceuticals Inc
F:RN3N
Revenue
$54k
CAGR 3-Years
-86%
CAGR 5-Years
-77%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Arena Pharmaceuticals Inc
Glance View

Market Cap
5.6B EUR
Industry
Biotechnology

Arena Pharmaceuticals Inc., once a promising player in the biotechnology space, carved out a niche in developing novel therapies aimed at addressing unmet needs in various therapeutic areas. The company focused heavily on its proprietary drug discovery and development platform, which centered around designing and creating small molecules to activate specific receptor subtypes. This mechanism allows them to produce targeted treatments with fewer side effects, thus appealing to a market in search of more specialized therapies. At the core of Arena's portfolio was its work in the fields of cardiology, gastroenterology, and dermatology, where the company ambitiously advanced its drug candidates through meticulous research and clinical trials, hoping to bring these innovations to patients worldwide. Arena's revenue-generating strategy primarily revolved around developing these new pharmaceuticals to the point where they became attractive for partnerships or acquisitions. The company often engaged in strategic collaborations with larger pharmaceutical players, licensing its products under development, which provided crucial funding for ongoing research while retaining some rights to future revenues. This model allowed Arena to leverage the market reach and financial muscle of its partners without bearing the full brunt of commercializing a drug. This symbiotic relationship was critical for Arena’s financial stability, offering a combination of upfront payments, milestone achievements, and eventual royalties. In a constantly evolving and competitive biopharmaceutical landscape, Arena’s approach aimed to balance innovative breakthroughs with practical business acumen.

RN3N Intrinsic Value
Not Available
A

See Also

What is Arena Pharmaceuticals Inc's Revenue?
Revenue
54k USD

Based on the financial report for Dec 31, 2021, Arena Pharmaceuticals Inc's Revenue amounts to 54k USD.

What is Arena Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
-77%

Over the last year, the Revenue growth was -82%. The average annual Revenue growth rates for Arena Pharmaceuticals Inc have been -86% over the past three years , -77% over the past five years .

Back to Top